Xia Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xia Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Hui Fang
Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
1 shared publication- Huiyun Pan
Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
1 shared publication Lihong Wang
Department of Geratology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China
1 shared publication- Senxiang Yan
Department of Radiation Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication Yalin Xie
Department of Radiotherapy, Hangzhou Tumor Hospital, Hangzhou 310000, Zhejiang, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 July 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 6581-6592
Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics
Background: Differentiation antagonizing non-protein-coding RNA (DANCR) is a novel long noncoding RNA. Recent studies have shown that DANCR is aberrantly expressed in several types of cancer and is associated with poor outcomes. However, the clinical diagnostic significance of DANCR in tumors is not completely understood. Methods: We searched the PubMed, Medline, Web of Science, EMBASE, Cochrane Library, and Ovid databases (up to December 30, 2018) for relevant literature. A total of 11 studies with 945 cancer patients were included in the present meta-analysis. We further validated the results using The Cancer Genome Atlas (TCGA) dataset. Results: High expression of DANCR significantly predicted poor overall survival (low expression group vs high expression group; HR = 0.56, 95% CI=[0.43, 0.72], = 0.000); this was validated using TCGA. Moreover, DANCR expression was associated with advanced tumor node metastasis stage (I+II: III+IV; OR=0.22, 95% CI=[0.14, 0.35], P=0.001) and lymph node metastasis (no:yes; OR=0.21, 95% CI=[0.13, 0.35], P=0.001). Conclusion: Our results suggest that elevated DANCR is related to poor clinical outcomes and could serve as a potential prognostic biomarker of cancer.
- 1 July 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 6581-6592
Open AccessLong noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics
Background: Differentiation antagonizing non-protein-coding RNA (DANCR) is a novel long noncoding RNA. Recent studies have shown that DANCR is aberrantly expressed in several types of cancer and is associated with poor outcomes. However, the clinical diagnostic significance of DANCR in tumors is not completely understood. Methods: We searched the PubMed, Medline, Web of Science, EMBASE, Cochrane Library, and Ovid databases (up to December 30, 2018) for relevant literature. A total of 11 studies with 945 cancer patients were included in the present meta-analysis. We further validated the results using The Cancer Genome Atlas (TCGA) dataset. Results: High expression of DANCR significantly predicted poor overall survival (low expression group vs high expression group; HR = 0.56, 95% CI=[0.43, 0.72], = 0.000); this was validated using TCGA. Moreover, DANCR expression was associated with advanced tumor node metastasis stage (I+II: III+IV; OR=0.22, 95% CI=[0.14, 0.35], P=0.001) and lymph node metastasis (no:yes; OR=0.21, 95% CI=[0.13, 0.35], P=0.001). Conclusion: Our results suggest that elevated DANCR is related to poor clinical outcomes and could serve as a potential prognostic biomarker of cancer.